HC Wainwright reiterated their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report report published on Thursday morning, Marketbeat.com reports. HC Wainwright currently has a $10.00 target price on the stock, up from their prior target price of $6.00.

A number of other equities research analysts have also recently commented on GALT. ValuEngine cut Galectin Therapeutics from a sell rating to a strong sell rating in a research report on Thursday, September 21st. Seaport Global Securities restated a buy rating and set a $5.00 target price on shares of Galectin Therapeutics in a research report on Friday, October 6th. Roth Capital initiated coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They set a buy rating and a $8.00 target price on the stock. Finally, Zacks Investment Research upgraded Galectin Therapeutics from a hold rating to a buy rating and set a $2.75 target price on the stock in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and an average target price of $4.55.

Galectin Therapeutics (NASDAQ GALT) traded up $0.42 during trading hours on Thursday, hitting $2.43. The stock had a trading volume of 4,246,100 shares, compared to its average volume of 430,631. Galectin Therapeutics has a 52-week low of $0.88 and a 52-week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. analysts predict that Galectin Therapeutics will post -0.52 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of GALT. Vanguard Group Inc. boosted its holdings in Galectin Therapeutics by 18.2% in the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after buying an additional 134,165 shares during the last quarter. Advisor Group Inc. boosted its holdings in Galectin Therapeutics by 10.4% in the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after buying an additional 45,700 shares during the last quarter. Virtu KCG Holdings LLC boosted its holdings in Galectin Therapeutics by 24.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after buying an additional 21,008 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Galectin Therapeutics by 4.4% in the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares during the last quarter. Institutional investors own 11.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Galectin Therapeutics (GALT) Rating Reiterated by HC Wainwright” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/galectin-therapeutics-galt-rating-reiterated-by-hc-wainwright/1757420.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.